FGFR2 Genetic Variant C.1019A > G p.(Tyr340Cys) in a Fetus with Pfeiffer Type II Syndrome Diagnosed by a Combination of 3D Ultrasound Phenotyping and DNA Sequencing
Scalia MS. et al, (2025), Journal of Fetal Medicine
Considerations for gestational age, delivery indication, and therapies in preeclampsia prediction.
Palma Dos Reis CR. et al, (2025), Am J Obstet Gynecol
Soluble fms-like tyrosine kinase 1-to-placental growth factor ratio predicts time to delivery and mode of birth.
Palma Dos Reis CR. et al, (2025), Am J Obstet Gynecol, 232
Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
Bacon I. et al, (2024), Lancet, 404, 750 - 751
The ratio of soluble fms–like tyrosine kinase 1 to placental growth factor predicts time to delivery and mode of birth in patients with suspected preeclampsia- a secondary analysis of the INSPIRE trial
PALMA DOS REIS CR. et al, (2024), American Journal of Obstetrics and Gynecology
MicroRNA analysis of medium/large placenta extracellular vesicles in normal and preeclampsia pregnancies
Awoyemi T. et al, (2024), Frontiers in Cardiovascular Medicine, 11
Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road
Thadhani R. et al, (2024), The FASEB Journal, 38
Serial placental growth factor-based testing in pre-eclampsia
Cerdeira AS. and Karumanchi SA., (2024), The Lancet, 403, 588 - 589
A cross-sectional analysis of syncytiotrophoblast membrane extracellular vesicles–derived transcriptomic biomarkers in early-onset preeclampsia
Awoyemi T. et al, (2023), Frontiers in Cardiovascular Medicine, 10
The sFlt1/PlGF ratio predicts faster fetal deterioration in early fetal growth restriction: A historical cohort study.
Palma Dos Reis CR. et al, (2023), Acta Obstet Gynecol Scand
Novel therapeutic and diagnostic approaches for preeclampsia.
Vatish M. et al, (2023), Curr Opin Nephrol Hypertens, 32, 124 - 133
Preeclampsia and syncytiotrophoblast membrane extracellular vesicles (STB-EVs).
Awoyemi T. et al, (2022), Clin Sci (Lond), 136, 1793 - 1807
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial.
Kifle MM. et al, (2022), BMC Pregnancy Childbirth, 22
Paracetamol use in pregnancy — neglecting context promotes misinterpretation
O’Sullivan J. et al, (2022), Nature Reviews Endocrinology
Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1/placental growth factor ratio ≤38: secondary analysis of the Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia
Cerdeira AS. et al, (2022), American Journal of Obstetrics and Gynecology, 226, 443 - 445
Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences
Cerdeira AS. et al, (2022), The Lancet, 399, 554 - 554
Is Prolonging Gestation in Preeclampsia For Better or Worse in Preventing Cardiovascular Disease?
Cerdeira AS. et al, (2021), Hypertension, 78, 1395 - 1397
The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia.
Cerdeira AS. et al, (2021), Am J Obstet Gynecol